Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 27, 2015 6:14 AM ET


Company Overview of Taiho Pharmaceutical Co., Ltd.

Company Overview

Taiho Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products. Its products include S-1, an oral antimetabolite and a combination of pharmacological compounds; ABI-007(Abraxane, a human serum albumin-bound paclitaxel; TSU-68, an orally administered, small-molecule, multiple receptor tyrosine kinase inhibitor; TAS-102, a novel combination antitumor agent; TAS-118, an antimetabolite solution; and ET-743(trabectedine), a synthetic derivative of a substance that was originally extracted from the colonial tunicate ecteinascidia turbinata. The company’s products also comprise TAS-114, an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism; TAS...

1-27 Kandanishiki-cho


Tokyo,  101-8444


Founded in 1963


81 3 3294 4527


81 3 3233 4057

Key Executives for Taiho Pharmaceutical Co., Ltd.

President and Representative Director
Chief Executive Officer of Otsuka Holdings Co., Ltd., President of Otsuka Holdings Co., Ltd. and Representative Director of Otsuka Holdings Co., Ltd.
Age: 64
Head of Production Division - Cmc Center and Director
Compensation as of Fiscal Year 2014.

Taiho Pharmaceutical Co., Ltd. Key Developments

Taiho Pharmaceutical Co., Ltd. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Taiho Pharmaceutical Co., Ltd. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Taiho Pharmaceutical Co., Ltd. Announces Termination of Phase III Clinical Trial of Carcinoma

Taiho Pharmaceutical Co., Ltd. announced on July 31 its decision to terminate a Phase III clinical trial (ORIENTAL trial)of the angiogenesis inhibitor TSU-68 (orantinib) in patients with hepatocellular carcinoma. This trial was a randomized, double-blind trial of hepatocellular carcinoma patients who were treated by transcatheter arterial chemoembolization, comparing two arms, TSU-68 arm (TACE plus TSU-68) and placebo arm (TACE plus placebo). The purpose of the trial was to demonstrate superiority of TSU-68 arm in overall survival. A total of 889 patients were enrolled from December 2010 to November 2013 and follow-up was scheduled until November 2016. This trial was conducted in Japan, South Korea, and Taiwan. An independent data monitoring committee conducted an interim analysis, the results of which indicated that the pre-determined standard related to the primary endpoint of overall survival was not met, and they therefore recommended that the trial be terminated. Based on this recommendation, Taiho Pharmaceutical made the decision to terminate the trial and communicated to the relevant regulatory authorities as well as all the principal investigators that the trial had been terminated.

Taiho Pharmaceutical Co., Ltd. Announces Executive Changes

Taiho Pharmaceutical Co., Ltd. announced that changes of directors were approved on June 11, 2014 at Taiho's annual general shareholders' meeting and the meeting of Board of Directors. Koichi Matsuda was appointed as Executive Vice President (Board Member), Taiho Pharmaceutical Co., Ltd., effective June 11, 2014. Koichi Matsuda’s previous position was Executive Vice President and Representative Director, Taiho Pharmaceutical Co., Ltd. Tsuyoshi Tsukamoto as appointed as Director (Board Member), Head of Production Division, CMC Center, Taiho Pharmaceutical Co., Ltd., effective June 11, 2014. Tsuyoshi Tsukamoto’s previous position was Operating Officer, Head of Production Division, CMC Center, Taiho Pharmaceutical Co., Ltd. Naofumi Moriwaki resigned as Director (Board Member), Taiho Pharmaceutical Co., Ltd., effective June 11, 2014.

Similar Private Companies By Industry

Company Name Region
Ryukakusan Co., Ltd. Asia
PRISM Pharma Co.,Ltd. Asia
Muromachi Chemicals Inc. Asia
Anaeropharma Science, Inc. Asia
TTI ellebeau, Inc. Asia

Recent Private Companies Transactions

Fund Raising
June 1, 2014
Remiges Biopharma Fund, LP

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Taiho Pharmaceutical Co., Ltd., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at